Eupraxia Pharmaceuticals Secures $63.2M in New Offering, Extends Cash Runway to H2 2028 Amidst Positive Clinical Progress
EPRX has more than doubled off its 52-week low of $2.68.
Summary
Eupraxia Pharmaceuticals reported increased net losses for 2025 but significantly extended its cash runway into H2 2028 through two substantial public offerings totaling over $140 million. The company also announced positive clinical data for its lead EoE candidate, EP-104GI, and a strategic shift to prioritize its development.
Key Events · Financing and Capital Events · EPRX
-
Successful 2026 Public Offering
The company closed a public offering on February 20, 2026, raising approximately $63.2 million in gross proceeds from the issuance of common shares and pre-funded warrants. This follows a $80.5 million offering in September 2025.
-
Extended Cash Runway
With the proceeds from recent offerings, the company anticipates its cash resources will be sufficient to fund planned operations into the second half of 2028, significantly de-risking near-term liquidity concerns.
-
Positive EP-104GI Clinical Data & Phase 3 Plans
Eupraxia announced positive tissue health data from its RESOLVE trial for EP-104GI in EoE, demonstrating near-complete improvement on biopsy in the highest dosed group. The company plans to initiate a Phase 3 program for EP-104GI.
-
Strategic Shift for EP-104IAR Program
The company is evaluating funding alternatives for the continued development of EP-104IAR (Osteoarthritis) and intends to use capital previously identified for this program to advance EP-104GI, indicating a strategic prioritization.
Analysis · EPRX · Life Sciences
Eupraxia Pharmaceuticals filed its annual report for the fiscal year ended December 31, 2025, revealing a net loss of $38.6 million for the year, an increase from $25.5 million in 2024, driven by higher research and development and general and administrative expenses. Despite the increased losses, the company significantly bolstered its financial position through two major capital raises. A public offering in September 2025 generated approximately $80.5 million, and a subsequent offering that closed on February 20, 2026, raised approximately $63.2 million in gross proceeds. These financings, combined with existing cash, are projected to fund operations into the second half of 2028, providing crucial runway for a clinical-stage biotechnology company. The company also reported positive tissue health data from its ongoing RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) and plans to advance this program to Phase 3. Concurrently, Eupraxia is evaluating funding alternatives for EP-104IAR (Osteoarthritis) and intends to reallocate capital previously earmarked for it to EP-104GI, signaling a strategic prioritization of its EoE program.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EPRX was trading at $7.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.9M. The 52-week trading range was $2.68 to $9.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.